This listing of claims will replace all prior version, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (canceled).

12. (previously presented): A method of treating inflammation, osteoporosis, an autoimmune disease, or atherosclerosis, comprising administering to a mammal, in need thereof, a therapeutically effective amount of an antibody to a M-CSF which inhibits the synergistic effect of said M-CSF on chemokine-mediated inflammation, osteoporosis, an autoimmune disease, or atherosclerosis, or a pharmaceutically acceptable salt thereof.

13. (canceled).

14. (previously presented): The method of claim 12, wherein the disease being treated is sepsis.

Claims 15-30 (canceled).

31. (previously presented): A method of treating inflammation in a mammal comprising administering to said mammal an effective amount of an antibody to a M-CSF.

32. (canceled).

33. (previously presented): The method of claim 31 wherein said inflammation is associated with arthritis.

34. (previously presented): A method of treating rheumatoid arthritis in a mammal comprising administering to said mammal an amount of an antibody to a M-CSF that is effective to treat said rheumatoid arthritis.

35. (canceled).

36. (previously presented): The method of claim 34 wherein said antibody is a monoclonal antibody.

37. (previously presented): The method of claim 31 comprising treating psoriasis by administering to said mammal an amount of an antibody to a M-CSF that is effective to treat said psoriasis.

38. (canceled).

39. (previously presented): The method of claim 37 wherein said antibody is a monoclonal antibody.

40. (canceled.)

41. (previously presented): The method of claim 14 wherein said antibody is a monoclonal antibody.

42. (currently amended): The method of claim 31 comprising treating asthma by administering to said mammal an amount of an antibody to a M-CSF that is effective to treat said ~~psoriasis~~ asthma.

43. (canceled).

44. (previously presented): The method of claim 33 wherein said antibody is a monoclonal antibody.

45. (previously presented) The method of claim 33, wherein said antibody is a monoclonal antibody, and wherein said M-CSF is a human M-CSF.

46. (previously presented) The method of claim 12, wherein said M-CSF is a human M-CSF.

47. (previously presented) The method of claim 31, wherein said M-CSF is a human M-CSF.

48. (previously presented) The method of claim 34, wherein said M-CSF is a human M-CSF.

49. (previously presented) The method of claim 36, wherein said M-CSF is a human M-CSF.

50. (previously presented) A method of treating rheumatoid arthritis in a mammal comprising administering to said mammal an amount of an antibody to a human M-CSF that is effective to treat said rheumatoid arthritis.